Precigen Dirección
Dirección controles de criterios 4/4
El CEO de Precigen es Helen Sabzevari , nombrado en Jan 2020, tiene una permanencia de 6.5 años. compensación anual total es $5.35M, compuesta por 18.7% salario y 81.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.06% de las acciones de la empresa, por valor de $20.84M. La antigüedad media del equipo directivo y de la junta directiva es de 6.5 años y 12.3 años, respectivamente.
Información clave
Helen Sabzevari
Chief Executive Officer (CEO)
US$5.4m
Compensación total
| Porcentaje del salario del CEO | 18.68% |
| Permanencia del CEO | 6.5yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 6.5yrs |
| Promedio de permanencia en la Junta Directiva | 12.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Precigen: Entering The Oncology 'Sweet Spot'
Summary Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call. Risks include competitive threats from INO-3107, but PGEN's commercial momentum remains strong. Read the full article on Seeking Alpha
PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking AlphaPrecigen: Successful Proof Of Platform, But Cash Worries Remain
Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking AlphaWe're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Precigen: RRP Targeting With AdenoVerse Technology Platform
Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking AlphaWill Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$383m |
| Dec 31 2025 | US$5m | US$1m | -US$430m |
| Sep 30 2025 | n/a | n/a | -US$426m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$5m | US$1m | -US$126m |
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$135m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$4m | US$1m | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$3m | US$1m | -US$80m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$3m | US$1m | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$20m | US$1m | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$100m |
| Jun 30 2020 | n/a | n/a | -US$122m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$1m | US$500k | -US$169m |
Compensación vs. Mercado: La compensación total ($USD5.35M) de Helen está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.19M).
Compensación vs. Ingresos: La compensación de Helen ha sido consistente con los resultados de la empresa en el último año.
CEO
Helen Sabzevari (64 yo)
Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 18.4yrs | US$600.00k | 3.76% $ 74.1m | |
| President | 6.5yrs | US$5.35m | 1.06% $ 20.8m | |
| Chief Financial Officer | 4.8yrs | US$1.49m | 0.099% $ 2.0m | |
| Chief Operating Officer | 6.4yrs | US$1.56m | 0.14% $ 2.8m | |
| Chief Legal Officer & Corporate Secretary | 15.5yrs | US$1.43m | 0.21% $ 4.2m | |
| Chief Commercial Officer | 2yrs | US$1.23m | 0.039% $ 770.7k | |
| VP & Head of Investor Relations | 8.5yrs | sin datos | sin datos | |
| Senior VP & Head of Research | no data | sin datos | sin datos | |
| Senior VP & Head of CMC | no data | sin datos | sin datos | |
| Senior VP & Head of Clinical Operations and Regulatory Affairs | 3.1yrs | sin datos | sin datos | |
| Chief Executive Officer of MBP Titan LLC | 7.5yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de PGEN es experimentado (6.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 18.4yrs | US$600.00k | 3.76% $ 74.1m | |
| President | 6.1yrs | US$5.35m | 1.06% $ 20.8m | |
| Independent Director | 14.7yrs | US$319.00k | 0.057% $ 1.1m | |
| Independent Director | 10.1yrs | US$313.00k | 0.35% $ 6.9m | |
| Independent Director | 18.4yrs | US$312.50k | 0.22% $ 4.3m | |
| Lead Independent Director | 12.3yrs | US$312.50k | 0.19% $ 3.8m | |
| Independent Director | 18.4yrs | US$300.00k | 0.34% $ 6.8m | |
| Independent Director | 2yrs | US$306.50k | 0.086% $ 1.7m | |
| Independent Director | 9.3yrs | US$313.00k | 0.19% $ 3.7m |
Junta con experiencia: Los miembros de la junta directiva de PGEN son experimentados ( 12.3 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/10 11:44 |
| Precio de las acciones al final del día | 2026/07/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Precigen, Inc. está cubierta por 10 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |